My Favorite Thing David Erritzoe shares the vial that sparked psychedelic thinking.

My Favorite Thing David Erritzoe shares the vial that sparked psychedelic thinking.

  • Words Tom Faber
  • Photograph Annie Lai

This vial is from our 2015 trial, which was the first study since the 1950s of using psychedelics to treat depression. It’s psilocybin that we received from a lab, rather than just being a compound that exists in a psychedelic mushroom that I could go out and find with my friends. This is actually a safe, very pure and controlled version of the same molecule that we can therefore give to people who are really unwell and in a fragile state.

So it symbolizes a reframing of how psychedelics are viewed, that they can reenter science and therapeutic testing for people who are suffering. We conducted the trial with the appropriate Home Office licenses, so it also represents the fact that we’re allowed to do this in the UK—it’s a validation that it’s legal, approved and safe enough ...

ISSUE 52

Take a look inside

The full version of this story is only available for subscribers

Want to enjoy full access? Subscribe Now

Subscribe Discover unlimited access to Kinfolk

  • Four print issues of Kinfolk magazine per year, delivered to your door, with twelve-months’ access to the entire Kinfolk.com archive and all web exclusives.

  • Receive twelve-months of all access to the entire Kinfolk.com archive and all web exclusives.

Learn More

Already a Subscriber? Login

Your cart is empty

Your Cart (0)